Incyte Pharmaceuticals, Inc.

Incyte Genomics, Inc.

Incyte Corporation

Applera Corporation

Pe Corporation (ny)

Applied Biosystems, LLC

Visby Medical, Inc.

Pe Corporation

Incyte Incorporation

Telomere Diagnostics, Inc.

Unitaq Bio

Karl J Guegler

Neil C Corley

Olga Bandman

Jennifer L Hillman

Preeti G Lal

Purvi Shah

Henry Yue

Y Tom Tang

Mariah R Baughn

Janice K Au-Young

Chandra Patterson

Ellen M Beasley

Valentina Di Francesco

Karen A Ketchum

Phillip R Hawkins

Gina A Gorgone

Jeffrey J Seilhamer

Craig G Wilde

Ruoying Tan

Marion Webster

Ingrid E Akerblom

Yalda Azimzai

Chandra S Arvizu

Surya K Goli

Roopa M Reddy

Michael J Rose

Gina A Gorgone Simone

Chunhua Yan

Susan G Stuart

Jiayin Li

Jennifer L Jackson

Lynn E Murry

Roger T Coleman

Gennady V Merkulov

Matthew R Kaser

Ming-Hui Wei

Kenneth J Livak

Caifu Chen

David Ruff

Dyung Aina M Lu

Trevor Woodage

Wei Shao

Mark Shannon

Kevin Hennessy

Preete Mathur

Ishwar Chandramouliswaran

Roopa Reddy

Dyung Aina Lu

Calvin B Harley

David Swenson

Eugene G Spier

Brian Ciopyk

Paul Michael Dentinger

Junming Yang

Joanne R Petithory

Teresa Abraham

Brandon Ma

Jue Lin

Kamal Kajouke

Mackenzie Hunt

Austin Phung

Brian M McKelligon

Y Tom Yang

Muzong Cheng

Anna H Postlethwaite

Craig G Wilde, Deceased

Jeffrey J Seilhamer, Deceased

Neil C Gorley

Sajeev Batra

Sven Henrichwark

Mark E Shannon

David W Ruff

Kevin M Hennessy

The disclosure relates generally to molecular diagnostic devices configured to amplifying a single nucleotide polymorphism (SNP) locus and discriminate between two or more allelic variants of the SNP, indicating presence or absence of a target allele. In some embodiments, the molecular diagnostic devices are capable of detecting, at point-of-care, SNPs associated with resistance or susceptibility to antibiotic treatment of organism infections. In other aspects, the disclosure provides methods of treatment for disease or disorders (e.g. organism infections) where treatment is guided by presence or absence of an allele at a SNP locus as determined by such molecular diagnostic devices.

Devices and methods for antibiotic susceptibility testing

Disclosed are methods and compositions for determining the average length or abundance of a first target nucleic by calculating the abundance of a first target nucleic acid (T) relative to the average abundance (S) of a second and a third target nucleic acid, in a single well using a separate detection label for each target nucleic acid. In various aspects, the first target nucleic acid is a telomere. In exemplary aspects, the disclosed methods and compositions can be used to determine the average telomere length in a biological sample. The average telomere length determined using the disclosed methods and compositions can be correlated to a variety of clinically important conditions and indices. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Multiplex quantitative PCR

The invention provides human signal peptide-containing proteins (HSPP) and polynucleotides which identify and encode HSPP. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HSPP.

Methods for detecting expression levels of human signal peptide-containing proteins (HSPP)

Provided herein are methods and compositions for performing PCR with primers with blocked 3'-ends that are unblocked when these primers anneal to the template. The multiplexed PCR can be used as real-time qPCR, for end-point detection or as enrichment method for next generation sequencing (NGS). Also described herein are methods and compositions to improve sensitivity of mutation-specific PCR when targeting closely-spaced mutations.

Methods and compositions for PCR using blocked and universal primers

The present teachings provide methods, compositions, and kits for detecting the presence of protein aggregates. In some embodiments, the protein aggregate is treated with a labeled precursor, and the labeled precursor is incorporated into the protein aggregate to form a labeled protein aggregate. The labeled protein aggregate is then measured, thus detecting the presence of the protein aggregate. In some embodiments, the labeled protein aggregate is detected by interaction of labeled precursors, for example by a proximity ligation assay.

Methods, compositions, and kits for detecting protein aggregates

Methods for treating colon cancer and inflammation associated with overexpression of human signal peptide-containing proteins

Antibodies which bind to signal peptide-containing molecules

Compositions comprising signal peptide-containing proteins

The present teachings provide methods, compositions, and kits for quantifying target polynucleotides. In some embodiments, a reverse stem-loop ligation probe is ligated to the 3' end of a target polynucleotide, using a ligase that can ligate the 3&#x2032; end of RNA to the 5&#x2032; end of DNA using a DNA template, such as T4 DNA ligase. Following digestion to form an elongated target polynucleotide with a liberated end, a reverse transcription reaction can be performed, followed by a PCR. In some embodiments, the methods of the present teachings can discriminate between polymorphic polynucleotides that vary by as little as one nucleotide.

Method to quantify siRNAs, miRNAs and polymorphic miRNAs

The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN.

Human transmembrane proteins

Polynucleotides encoding signal peptide-containing molecules

The invention provides human protease molecules (HUPM) and polynucleotides which identify and encode HUPM. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of HUPM.

Methods for detecting expression of human protease molecules

The present invention provides nucleotide and amino acid sequences that identify and encode a novel expressed chemokine (ADEC) from inflamed adenoid tissue. The present invention also provides for antisense molecules to the nucleotide sequences which encode ADEC, expression vectors for the production of purified ADEC, antibodies capable of binding specifically to ADEC, hybridization probes or oligonucleotides for the detection of ADEC-encoding nucleotide sequences, genetically engineered host cells for the expression of ADEC, diagnostic tests for inflammation or disease based on ADEC-encoding nucleic acid molecules or antibodies capable of binding specifically to ADEC.

Methods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid

Growing community of inventors

Menlo Park, CA, United States of America

Karl J Guegler